10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms
Key Takeaways
- Acute effects occur during or shortly after therapy and resolve, long-term effects begin during therapy and persist afterward, and late effects appear months to decades after treatment has ended.
- The typical chemotherapy neutrophil nadir occurs 7 to 14 days after administration with recovery by day 21 to 28, while carboplatin causes a delayed platelet nadir around day 21.
- Acute radiation toxicity affects rapidly dividing tissues within 90 days, whereas late radiation toxicity reflects fibrosis and endarteritis and appears after 90 days to years.
- CTCAE version 5.0 grades adverse events from 1 (mild) to 5 (death), and grade 3 generally means severe but not immediately life-threatening, usually triggering hospitalization or treatment interruption.
- Predicting the timing of a symptom is what allows prophylaxis: antiemetics before nausea, growth factors before nadir, and skin care before radiation dermatitis.
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms
Blueprint focus: ONCC Domain II.I — Etiology, incidence, and patterns for treatment-related symptoms (acute, late, long term). This blueprint item is about timing. Knowing when a toxicity will appear is what converts reactive management into prophylaxis.
Three Timing Categories
| Category | Definition | Examples |
|---|---|---|
| Acute | Occurs during or within days to weeks of treatment; resolves after the drug clears or the tissue recovers | Nausea and vomiting, myelosuppression, mucositis, acute radiation dermatitis, infusion reactions, cholinergic diarrhea |
| Long-term (persistent) | Begins during treatment and continues after it ends | Chemotherapy-induced peripheral neuropathy, cancer-related fatigue, lymphedema, cognitive impairment, premature ovarian insufficiency |
| Late | Appears months to decades after treatment has ended, in a patient who had recovered | Anthracycline cardiomyopathy, radiation-induced second malignancy, radiation fibrosis, therapy-related myeloid neoplasm, hypothyroidism after neck radiation |
The distinction is not academic. Acute effects are managed with prophylaxis and supportive care; long-term effects are managed with rehabilitation and adaptation; late effects require lifelong surveillance in a patient who otherwise considers themselves cured.
Predictable Acute Timelines
Myelosuppression
| Cell line | Typical nadir | Typical recovery | Clinical consequence |
|---|---|---|---|
| Neutrophils | Days 7 to 14 | Days 21 to 28 | Febrile neutropenia risk peaks at nadir |
| Platelets | Days 10 to 14 | Days 21 to 28 | Bleeding risk |
| Red cells | Cumulative over cycles | Slow; life span roughly 120 days | Anemia and fatigue accumulate rather than nadir |
Important exceptions: carboplatin produces a delayed platelet nadir around day 21 with thrombocytopenia as its dose-limiting toxicity; nitrosoureas such as carmustine and lomustine produce a delayed and prolonged nadir at 4 to 6 weeks, which is why they are given every 6 weeks rather than every 3.
Growth factor timing follows from this: pegfilgrastim or filgrastim is given 24 to 72 hours after chemotherapy completion, before the nadir, and never within 24 hours of cytotoxic therapy.
Nausea and vomiting
- Acute: within 24 hours of administration, peaking at 5 to 6 hours.
- Delayed: after 24 hours, typically days 2 to 5, and characteristic of cisplatin, carboplatin, and anthracycline-cyclophosphamide combinations.
- Anticipatory: before the next cycle, a conditioned response created by inadequate control of a prior cycle.
- Breakthrough and refractory describe failure of prophylaxis during and across cycles respectively.
Diarrhea
- Irinotecan early (cholinergic): during or within 24 hours, with diaphoresis, cramping, lacrimation, and salivation; treated with atropine.
- Irinotecan late (secretory): after 24 hours, from the SN-38 metabolite; treated with high-dose loperamide.
- Immune checkpoint inhibitor colitis: typically weeks to months after initiation, and can appear after the drug has been stopped.
Mucositis
Onset 5 to 10 days after chemotherapy, coinciding with the neutrophil nadir, and healing over 1 to 2 weeks as counts recover. With radiation, mucositis begins around the second week of treatment and peaks at completion.
Radiation
- Acute (within 90 days): rapidly dividing tissues — skin, mucosa, bone marrow within the field, bowel. Erythema begins around 2 to 3 weeks; dry then moist desquamation follows.
- Subacute: radiation pneumonitis typically presents 1 to 6 months after thoracic radiation.
- Late (after 90 days to years): fibrosis, endarteritis obliterans, necrosis, strictures, xerostomia, lymphedema, hypothyroidism, and second malignancy.
Infusion reactions
- Non-IgE cytokine or complement-mediated: during the first or second infusion, characteristic of taxanes and of monoclonal antibodies such as rituximab.
- True IgE-mediated hypersensitivity: requires prior sensitization and characteristically appears after multiple cycles, classically around cycles 6 to 8 with platinum agents.
Modality-Specific Late Effects
| Modality | Late effect | Surveillance |
|---|---|---|
| Anthracyclines | Cardiomyopathy and heart failure, dose-dependent above roughly 450 to 550 mg/m² of doxorubicin, presenting years later | Serial echocardiography; lifelong awareness |
| Bleomycin | Pulmonary fibrosis above roughly 400 units cumulative | PFTs with DLCO; avoid high FiO2 during anesthesia |
| Cisplatin | Sensorineural hearing loss, tinnitus, chronic kidney disease, persistent neuropathy, hypomagnesemia | Audiometry, renal function, magnesium |
| Alkylating agents | Infertility, premature ovarian insufficiency, therapy-related MDS/AML at 5 to 7 years | Annual CBC; endocrine and fertility follow-up |
| Topoisomerase II inhibitors | Therapy-related AML at 1 to 3 years with KMT2A rearrangement | Annual CBC |
| Radiation (any field) | Fibrosis, second malignancy after more than 10 years, tissue-specific damage | Field-specific lifelong surveillance |
| Neck radiation | Hypothyroidism, carotid stenosis, xerostomia, dental caries, osteoradionecrosis | TSH every 6 to 12 months; dental follow-up |
| Chest radiation | Coronary disease, valvular disease, breast cancer, pulmonary fibrosis | Cardiac risk management; breast MRI and mammography per Section 2.4 |
| Pelvic radiation | Infertility, sexual dysfunction, bladder and bowel toxicity, insufficiency fractures | Symptom-directed |
| Immune checkpoint inhibitors | Permanent endocrinopathy — hypothyroidism, hypophysitis, type 1 diabetes, adrenal insufficiency | Lifelong hormone replacement; TSH monitoring |
| HSCT | Chronic GVHD, secondary malignancy, endocrine failure, cataracts, avascular necrosis | Transplant long-term follow-up protocols |
| Androgen deprivation therapy | Osteoporosis, metabolic syndrome, cardiovascular risk, sarcopenia | DEXA, lipids, glucose, exercise |
| Aromatase inhibitors | Bone loss, arthralgia | DEXA every 2 years, calcium and vitamin D |
Grading With CTCAE Version 5.0
| Grade | Meaning |
|---|---|
| 1 | Mild; asymptomatic or mild symptoms; observation only |
| 2 | Moderate; minimal, local, or non-invasive intervention indicated; limits instrumental activities of daily living |
| 3 | Severe or medically significant but not immediately life-threatening; hospitalization or prolongation indicated; disabling; limits self-care |
| 4 | Life-threatening consequences; urgent intervention indicated |
| 5 | Death related to the adverse event |
Grading drives action. Most protocols hold therapy at grade 3, and grade 2 immune-related adverse events already trigger corticosteroids and drug interruption. Grade the event, then apply the label's modification table — do not improvise.
Turning Timing Knowledge Into Prophylaxis
- Before cycle 1, name the expected toxicities and their expected day, and give the patient a written calendar.
- Prescribe prophylaxis before the symptom: guideline antiemetics for the emetogenic level, growth factors when regimen risk is 20% or more, antimicrobial prophylaxis where indicated, skin care from the first day of radiation, and bowel prophylaxis with the first opioid.
- Schedule laboratory checks at the predicted nadir, not at an arbitrary interval.
- Teach the specific red flags and the number to call, with fever above 38.0 to 38.3 °C as an emergency rather than a next-business-day problem.
- Document toxicity by CTCAE grade so that the next clinician can apply the correct dose modification.
A patient receiving carboplatin-based chemotherapy has a normal complete blood count on day 14. On day 21 her platelet count is 38,000/µL. How should the nurse practitioner interpret this finding?
A 46-year-old woman completed doxorubicin-based adjuvant chemotherapy 7 years ago and has been well. She now presents with exertional dyspnea, orthopnea, and an ejection fraction of 34%. How should this toxicity be classified?
A patient develops immune-mediated colitis with 5 stools per day above baseline and abdominal cramping, but no hemodynamic instability and no need for hospitalization. Using CTCAE version 5.0, how is this graded, and what does that grade generally imply?